{"id":767675,"date":"2023-07-05T07:37:18","date_gmt":"2023-07-05T11:37:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/"},"modified":"2023-07-05T07:37:18","modified_gmt":"2023-07-05T11:37:18","slug":"medicenna-extends-period-to-exercise-certain-warrants-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/","title":{"rendered":"Medicenna Extends Period to Exercise Certain Warrants"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO and HOUSTON, July  05, 2023  (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or the\u00a0\u201cCompany\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding common share purchase warrants of the Company (the\u00a0\u201cWarrants\u201d) originally issued on October\u00a017, 2019 as part of a public offering of units of the Company. Each warrant is exercisable for a common share of the Company (the\u00a0\u201cCommon Shares\u201d) at a price of $1.75 per Common Share and set to expire on July 17, 2023.<\/p>\n<p align=\"justify\">The Company has extended the expiry date of such Warrants until October\u00a017, 2024, with such extension being effective on July 17, 2023. All other terms of the Warrants, including the exercise price, remain unchanged. None of the outstanding warrants are held by insiders.<\/p>\n<p align=\"justify\">\n        <strong>About Medicenna <\/strong>\n      <\/p>\n<p align=\"justify\">Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna\u2019s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna\u2019s early-stage BiSKITs\u2122 program, (\u201cBifunctional SuperKine ImmunoTherapies\u201d) is designed to enhance the ability of Superkines to treat immunologically \u201ccold\u201d tumors. Medicenna\u2019s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA\/EMA, respectively.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts including, but not limited to, statements related to the extension of the term of the Warrants. Forward-looking statements are often identified by terms such as \u201cwill\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201canticipate\u201d, \u201cexpects\u201d, \u201cbelieves\u201d, \u201cseeks\u201d and similar expressions. All statements other than statements of historical fact, included in this release, are forward-looking statements that are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company\u2019s expectations include the risks detailed in the annual information form and Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in\u00a0Canada\u00a0and\u00a0the\u00a0United States.<\/p>\n<p align=\"justify\">The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTdjOGE5NGYtYzA1Ny00MzllLTkyNWItMDk0ODg1ZTczOGJkLTExMzQwNTI=\/tiny\/Medicenna-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Further Information\r\n\r\nFor further information about the Company please contact:\r\n\r\nElizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com\r\n\r\nMedia Contact\r\n\r\nFor media inquiries, please contact:\r\n\r\nTony Russo, Russo Partners, 212-845-4251, tony.russo@russopartnersllc.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or the\u00a0\u201cCompany\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding common share purchase warrants of the Company (the\u00a0\u201cWarrants\u201d) originally issued on October\u00a017, 2019 as part of a public offering of units of the Company. Each warrant is exercisable for a common share of the Company (the\u00a0\u201cCommon Shares\u201d) at a price of $1.75 per Common Share and set to expire on July 17, 2023. The Company has extended the expiry date of such Warrants until October\u00a017, 2024, with such extension being effective on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Medicenna Extends Period to Exercise Certain Warrants&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-767675","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medicenna Extends Period to Exercise Certain Warrants - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicenna Extends Period to Exercise Certain Warrants - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or the\u00a0\u201cCompany\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding common share purchase warrants of the Company (the\u00a0\u201cWarrants\u201d) originally issued on October\u00a017, 2019 as part of a public offering of units of the Company. Each warrant is exercisable for a common share of the Company (the\u00a0\u201cCommon Shares\u201d) at a price of $1.75 per Common Share and set to expire on July 17, 2023. The Company has extended the expiry date of such Warrants until October\u00a017, 2024, with such extension being effective on &hellip; Continue reading &quot;Medicenna Extends Period to Exercise Certain Warrants&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-05T11:37:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medicenna Extends Period to Exercise Certain Warrants\",\"datePublished\":\"2023-07-05T11:37:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/\"},\"wordCount\":588,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/\",\"name\":\"Medicenna Extends Period to Exercise Certain Warrants - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=\",\"datePublished\":\"2023-07-05T11:37:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-extends-period-to-exercise-certain-warrants-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicenna Extends Period to Exercise Certain Warrants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicenna Extends Period to Exercise Certain Warrants - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/","og_locale":"en_US","og_type":"article","og_title":"Medicenna Extends Period to Exercise Certain Warrants - Market Newsdesk","og_description":"TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or the\u00a0\u201cCompany\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding common share purchase warrants of the Company (the\u00a0\u201cWarrants\u201d) originally issued on October\u00a017, 2019 as part of a public offering of units of the Company. Each warrant is exercisable for a common share of the Company (the\u00a0\u201cCommon Shares\u201d) at a price of $1.75 per Common Share and set to expire on July 17, 2023. The Company has extended the expiry date of such Warrants until October\u00a017, 2024, with such extension being effective on &hellip; Continue reading \"Medicenna Extends Period to Exercise Certain Warrants\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-05T11:37:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medicenna Extends Period to Exercise Certain Warrants","datePublished":"2023-07-05T11:37:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/"},"wordCount":588,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/","name":"Medicenna Extends Period to Exercise Certain Warrants - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=","datePublished":"2023-07-05T11:37:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2ODk2OCM1Njc3MDMzIzIxMjI0ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-extends-period-to-exercise-certain-warrants-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medicenna Extends Period to Exercise Certain Warrants"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/767675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=767675"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/767675\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=767675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=767675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=767675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}